Here is Why Alphatec (ATEC) is One of the Best Cheap Stocks Under $10 to Buy in June
Alphatec Holdings (ATEC) reported Q1 2026 results on May 5, with total revenue up 14% to $192 million and surgical revenue up 17%. The company posted non-GAAP adjusted EBITDA of $21 million and said a new bank facility would cut annual interest expense by over $6 million and extend maturities to 2031. For 2026, it expects revenue of about $882 million and adjusted EBITDA of about $134 million.
How this was made
The 30-second read
Why it matters
Surgical growth metrics and quantified adjusted EBITDA/FCF guidance can support a valuation re-rate, while EOS expectation adjustments introduce execution risk.
Market read
Near-term trading interest is driven by the combination of growth (surgical revenue/case volume), profitability (adjusted EBITDA expansion), and cash/financing improvements (interest expense reduction; debt maturity extension; ending cash/FCF).
What to watch
The article doesn’t quantify segment margin impact or provide details on the bank facility terms beyond interest savings and maturity extension, limiting precision on leverage/credit risk.
Background
The piece summarizes Alphatec’s Q1 2026 performance and full-year 2026 outlook, emphasizing surgical growth and improved financing/FCF outlook.
Ticker impact
Alphatec’s May 5 Q1 2026 results included 17% surgical revenue growth, $21M non-GAAP EBITDA, and a new bank facility cutting interest by $6M+ annually.
Mild-to-moderate positive bias; upside depends on whether investors focus on surgical growth + FCF trajectory versus EOS uncertainty.
The article cites specific operating growth (surgical revenue/case volume/surgeon users), quantified profitability (adjusted EBITDA), and quantified financing benefit (interest expense reduction, maturity extension), all of which are direct valuation inputs. However, it’s framed as a “cheap stock” pitch and doesn’t provide new post-earnings market reaction data.
Market effects
Positive read-through for spine/surgical medtech demand signals (surgical case volume and surgeon adoption).
None explicitly stated.
None explicitly stated.
Counterpoint
EOS business expectations were adjusted, so the market may discount surgical strength if EOS uncertainty worsens or margins don’t hold.
Key entities
- companyAlphatec Holdings Inc.
Spine-focused surgical solutions provider; reported Q1 2026 results and issued 2026 revenue/EBITDA/FCF expectations.
